The following is a summary of the Milestone Scientific Inc. (MLSS) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Q3 2024 revenue reached $2.5 million, up 22% year-over-year primarily driven by strong growth in the dental division.

• Gross profit for Q3 2024 was $1.8 million or 73% of revenue.

• Operating loss and net loss for Q3 2024 were approximately $1.5 million each, showing minimal change from the previous year.

• Cash and equivalents as of Sept 30, 2024 were $4.8 million with no long-term debt, supporting growth without the need for additional capital.

Business Progress:

• Significant international growth observed with a 57% increase in international dental sales.

• CompuFlo Epidural System is being adopted by leading pain management clinics, enhancing Milestone's growth in medical sectors.

• Expansion in Brazil and progress with Medicare reimbursement are set to drive further growth.

• Continued efforts to expand distribution and commercial partnerships in key regions.

Opportunities:

• Expanding Medicare reimbursement and adapting to different JMAC regions enhance the potential for significant U.S. market penetration.

• Market expansion opportunities in Brazil and broader Latin America following regulatory approval.

• The shift to e-commerce platform in the U.S. offers direct customer engagement and improved margins.

Risks:

• No explicit risks mentioned.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.